Treatment Advancements and Evidence for Emerging Therapies in Hormone Receptor-Positive Breast Cancer

NOTE: This session is part of the Live Intensive Studies and Clinical Sessions packages. All attendees may attend these thought-provoking and highly educational sessions. However, if you are board-certified, you must purchase the package(s) for your specialty to receive the recertification assessment and claim the recertification credit.

Hormone receptor-positive (HR+) breast cancer represents the majority (69%) of breast cancer cases. While comparatively, HER2+ and triple-negative breast cancer spaces have seen a number of practice-changing advancements in the past few years, HR+ breast cancer has seen relatively few until recently. Within both early-stage and metastatic settings of HR+ breast cancer, new FDA approvals have stirred an evolving treatment approach.

Newly approved treatments have the potential to cause significant toxicity and require pharmacists to be aware of specific preventative measures and monitoring parameters. Clinical controversies appear throughout this treatment setting given the rapidly evolving nature, particularly when it comes to treatment sequencing. This clinical session will assist pharmacists caring for this patient population to be well-versed in treatment nuances.

This activity is approved for Board-Certified Oncology Pharmacist (BCOP) recertification credit.